目的 分析卡瑞利珠单抗致多器官损伤不良反应的临床表现及特点，为临床安全用药提供参考。方法 检索知网、万方、维普、PubMed、Web of Science、Embase数据库，自2019年5月至2023年11月卡瑞利珠单抗致多器官损伤不良反应的案例报道，并对文献进行统计分析。结果 共检索到有效文献22篇，纳入病例22例，其中男性14例(63。64％)，女性8例(36。36％)。药物不良反应(ADR)发生年龄大于60岁有18例(81。82％);ADR发生时间多在10～35 d(18例，81。82％);累及的器官系统损害涉及肌肉骨骼16例次(72。73％)、心脏15例次(68。18％)、肝脏9例次(40。91％)、神经系统7例次(31。82％);其中16例(72。73％)患者经停药和(或)对症治疗后好转，6例(27。27％)死亡。结论 卡瑞利珠单抗致多器官损伤不良反应主要在老年患者中发生，骨骼肌及心肌损害较多，起病急、致死率高，需引起高度重视，临床使用时需加强用药监护，早期识别，及时处理。
Literature analysis of adverse reactions to multiple organ injury induced by camrelizumab
Objective To analyze the clinical manifestations and characteristics of adverse reactions to multi-organ injury caused by camrelizumab,and provide reference for clinical safe drug use. Methods Case reports of immune-related multiple organ injury induced by camrelizumab were searched from CNKI,Wanfang,VIP,PubMed,Web of Science and Embase databases from May 2019 to November 2023,and the literature was statistically analyzed. Results A total of 22 valid reports were retrieved,and 22 cases were included,including 14 males (63.64％) and 8 females (36.36％). Adverse drug reactions (ADRs) occurred in 18 cases at age over 60 (81.82％). ADRs occurred mostly in 10-35 days (18 cases,81.82％). The involved organ system damage involved musculoskeletal (16 cases,72.73％),heart (15 cases,68.18％),liver (9 cases,40.91％),nervous system (7 cases,31.82％). Among them,16 cases (72.73％) improved or recovered after drug withdrawal and/or symptomatic treatment,and 6 cases (27.27％) died. Conclusion The adverse reactions of multiple organ injury caused by camrelizumab mainly occurred in the elderly patients,and the skeletal muscle and myocardium were more damaged,with rapid onset and high mortality,which should be paid great attention to. In clinical use,it is necessary to strengthen drug monitoring,early identification and timely treatment.
CamrelizumabMultiple organ injuryAdverse reactionsLiterature system analysisImmunotherapyProgrammed death protein 1
NETL
NSTL
万方数据
